Lonafarnib (SCH66336)

For research use only. Not for use in humans.

目录号:S2797

Lonafarnib (SCH66336) Chemical Structure

CAS No. 193275-84-2

Lonafarnib (SCH66336) 是一种口服生物有效的FPTase抑制剂,作用于H-rasK-ras-4BN-ras,无细胞试验中IC50分别为1.9 nM, 5.2 nM和2.8 nM。Phase 3。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 3509.73 现货
RMB 1416.91 现货
RMB 2229.57 现货
RMB 4250.61 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Lonafarnib (SCH66336)发表文献14篇:

客户使用该产品的2个实验数据:

  • Huh-7/hNTCP cells were infected with in vitro generated HDV in the presence or absence of MyrB (50 nM) or lonafarnib (200 nM). After 5 days cells were labeled with HDAg#280, secondary AF488 and stained with DAPI. A representative of four independent experiments is shown.

    Antiviral Res, 2017, 141:116-123. Lonafarnib (SCH66336) purchased from Selleck.

  • Low-dose lonafarnib decreased HIF-1α expression without inhibiting cell growth in MDA-MB-231 cells. (A, B) Lonafarnib (1 μM) treatment for 24 h significantly decreased HIF-1α expression, which was normalized to that of GAPDH. In contrast, lonafarnib (1 μM) did not decrease HIF-2α expression.

    J Cell Physiol, 2017, 232(1):192-201. Lonafarnib (SCH66336) purchased from Selleck.

产品安全说明书

Transferase抑制剂选择性比较

生物活性

产品描述 Lonafarnib (SCH66336) 是一种口服生物有效的FPTase抑制剂,作用于H-rasK-ras-4BN-ras,无细胞试验中IC50分别为1.9 nM, 5.2 nM和2.8 nM。Phase 3。
靶点
H-ras [1]
(Cell-free assay)
N-ras [1]
(Cell-free assay)
K-ras-4B [1]
(Cell-free assay)
1.9 nM 2.8 nM 5.2 nM
体外研究

SCH66336在0.1 μM到8 μM浓度范围均可抑制头部和颈部鳞状细胞癌(HNSCC) 生长和诱导凋亡,抑制效果具有剂量和时间依赖性。SCH66336 (8 μM)可在SqCC/Y1细胞中抑制蛋白激酶B/Akt活性和磷酸化 Akt蛋白底物糖原合酶激酶(GSK)- 3β,转录叉因子和BAD[2]。SCH66336 对多细胞系有抗增殖作用,IC 50范围从0.6 μM 到32.3 μM [3] ; Lonafarnib诱导CCAAT /增强子结合蛋白同源蛋白(CHOP)依赖性DR5启动子的转录激活,从而诱导CHOP依赖性的DR5上调。Lonafarnib (< 10 μM) 可激活caspase - 8及其下游的半胱氨酸蛋白酶,从而诱导H1792细胞凋亡。Lonafarnib (5 μM)可增加DR5的细胞表面分布,增强肿瘤坏死因子相关凋亡诱导配体诱导的H1792细胞凋亡[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Cos-1 monkey kidney cells Mn60SpVv[3Srb36gZZN{[Xl? Mn3uTY5pcWKrdHnvckBw\iCScn;0[YlvKG[jcn7ld5ltfHKjboPm[ZJie2ViaX6gR49{NTFibX;ub4V6KGurZH7lfUBk\WyuczDlfJBz\XO|aX7nJGguWmG|LY\hcEwhUUN3ME2wMlAxOTlizszN MoT5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJzOUCzNFkoRjF{MUmwN|A6RC:jPh?=
COS-7 monkey cells NVjzO45[TnWwY4Tpc44h[XO|YYm= MYDJcohq[mm2aX7nJJRp\SCoYYLu[ZN6dGG2aX;uJI9nKEhvcnHzJJBzd3SnaX7zJIlvKEORUz23JI1wdmuneTDj[YxteyC2cnHud4lmdnSueTDlfJBz\XO|aX7nJGguemG|W2\hcFEzZS2FVlzTJIlvKHSqZTD3bI9t\SClZXzsJIF{e2G7LDDJR|UxRTBwMEGg{txO MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek86QDJ{NUW4K|46QDJ{NUW4QE9iRg>?
MCF-7 tumor cell line M4H5PWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NX7j[|JqS2:vcH;1coQhf2G|IH3lZZN2emWmIH\vdkBqdmirYnn0bY9vKG:oIF3DSk04KHS3bX;yJINmdGxibHnu[UBqdiCkcnXhd5QhfW6mZYKgd49nfCCjZ3HyJIF{e2G7LDDJR|UxRTBwMEWg{txO MknKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwQTh{MkW1PEc,QTh{MkW1PFww[T5?
HCT116 NFHJNGtIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NYHRdJVZS2:vcH;1coQhf2G|IH3lZZN2emWmIH\vdkBqdmirYnn0bY9vKG:oIFjDWFEyPiC2dX3vdkBk\WyuIHzpcoUhcW5iY3;sc44hfW6mZYKgd49nfCCjZ3HyJIF{e2G7LDDJR|UxRTBwMEeg{txO M2\LdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493Nzl6MkK1OVgoRjl6MkK1OVg9N2F-
NIH-H tumor cell lines MoLCS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHjQXlJEd22yb4Xu[EBi[mmuaYT5JJRwKGmwaHnibZQh[W6laH;yZYdmNWmwZHXw[Y5l\W62IHfyc5d1cCCxZjDOTWguUCC2dX3vdkBk\WyuIHzpcoV{KGmwIIPv[pQh[WejcjygTWM2OD1yLkC3NkDPxE1? MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek86QDJ{NUW4K|46QDJ{NUW4QE9iRg>?
NIH3T3 cells NFS1V|ZHfW6ldHnvckBie3OjeR?= MnTjTY5pcWKrdHnvckBw\iCUYYOg[oFzdmW|eXzheIlwdiCrbjDIMXJieyC2cnHud4Zwem2nZDDOTWg{XDNiY3XscJMtKEWFNUC9NE4yKM7:TR?= NWS5T2t{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUW0OVQzOjhpPkG1OFU1OjJ6PD;hQi=>
NIH-K tumor cell lines M{LtUWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MmPTR49ueG:3bnSgZYJqdGm2eTD0c{BqdmirYnn0JIFv[2ixcnHn[U1qdmSncHXu[IVvfCCpcn;3eIghd2ZiTlnIMWshfHWvb4KgZ4VtdCCuaX7ld{BqdiC|b3\0JIFo[XJuIFnDOVA:OC53IN88US=> MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek86QDJ{NUW4K|46QDJ{NUW4QE9iRg>?
Cos-1 NIS4NWRHfW6ldHnvckBie3OjeR?= M3TZUGlvcGmkaYTpc44hd2ZiUILveIVqdiCoYYLu[ZN6dHS{YX7z[oVz[XOnIHnuJGNwey1zIH3vcotmgSCtaXTu[Zkh[2WubIOg[ZhxemW|c3nu[{BJNVKjcz32ZYwtKEmFNUCgQUAxNjByMUmg{txONg>? NWHxPHdQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUKxPVA{ODlpPkGyNVkxOzB7PD;hQi=>
Cos-1 MXrGeY5kfGmxbjDhd5NigQ>? NF;YS4JG\m[nY4Sgc44hWmG|IIDyc4Nme3OrbnegbY4hS2:|LUGgcY9vc2W7IHvp[I5mgSClZXzsd{BmgHC{ZYPzbY5oKGWrdHjldkBJNVKjcz3WZYwhOTJvQ2\MV{BweiCKLWLhd{1X[WxzMjygTWM2OCB;IECuNFEh|ryPLh?= NXPpeo9rRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUC0NVE1QDVpPkGwOFEyPDh3PD;hQi=>
COS7 NWnaPYw5TnWwY4Tpc44h[XO|YYm= NHziT5VKdmirYnn0bY9vKG:oIF\UZZNmKGmwIHj1cYFvKEORU{egZ4VtdHNuIFnDOVAhRSByLkCxJO69VS5? M1PsRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyOUK1OFM{Lz5{MEmyOVQ{OzxxYU6=
H-Ras transformed cells M4LGU2Z2dmO2aX;uJIF{e2G7 NVzGVI8yUW6qaXLpeIlwdiCxZjDzc4Z1KGGpYYKgZ49td267IH\vdo1ifGmxbjDpckBJNVKjczD0doFve2[xcn3l[EBk\WyuczygTWM2OCB;IECuNFch|ryPLh?= MoTUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTV3MEGwOlUoRjF3NUCxNFY2RC:jPh?=
NIH3T3 NEfwOlZHfW6ldHnvckBie3OjeR?= MnuwSYZn\WO2aY\lJINwdmOnboTyZZRqd25iYXfhbY5{fCCKYT3SRXMheHKxY3Xzd4lv\yCrbjDOTWg{XDNicnHzMZRz[W6|Zn;ycYVlKGOnbHzzMEBGSzVyIE2gNE4yPiEQvF2u MorIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJ4NUeyPFQoRjF{NkW3Nlg1RC:jPh?=
NIH3T3 MnjXSpVv[3Srb36gZZN{[Xl? NXr5RVJ[XFChVGLBUnNRV1KWRWK6JIlvcGmkaYTpc44hd2ZiRF7SJIVn\my3eDCoSG5TQiB1IIXNLUBqdiCPRGKxMYV5eHKnc4PpcochVkmKM2SzJINmdGy|LDDJR|UxKD1iMj63JO69VS5? MlLEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTF4ME[zPFkoRjFzNkC2N|g6RC:jPh?=
A673 M3:xe5FJXFNiYYPzZZk> NVOyb3dmeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFG2O|Mh[2WubIO= NGPCXow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
DAOY M3fvR5FJXFNiYYPzZZk> MonwdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKESDT2mgZ4VtdHN? NUjrZ2ViRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Saos-2 NH21NnRyUFSVIHHzd4F6 MV7xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW2Gxcz2yJINmdGy| Ml\XQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
BT-37 NIXmTGxyUFSVIHHzd4F6 NFvEbI1yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStN|ch[2WubIO= MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
RD M17zTJFJXFNiYYPzZZk> MlXDdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKGIHPlcIx{ MlPNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
BT-12 NWnWWY17eUiWUzDhd5NigQ>? MVLxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvMUKgZ4VtdHN? NVr2cZN4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
MG 63 (6-TG R) MUHxTHRUKGG|c3H5 NX[xdpI1eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF3HJFY{KCh4LWTHJHIqKGOnbHzz MoDyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
NB1643 MojZdWhVWyCjc4PhfS=> NHfnVFRyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKxOlQ{KGOnbHzz M334OlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
OHS-50 M1T6N5FJXFNiYYPzZZk> MYrxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhV0iVLUWwJINmdGy| NVvZdlZjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh41 NUXWZZppeUiWUzDhd5NigQ>? MmXwdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqNEGgZ4VtdHN? M3XHc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SJ-GBM2 M1:yd5FJXFNiYYPzZZk> NEfuOVByUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1qtS2JOOiClZXzsdy=> M1jMdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC MUTxTHRUKGG|c3H5 Ml7xdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO= M3jEZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB-EBc1 M3XQO5FJXFNiYYPzZZk> M3rjOJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQj3FRoMyKGOnbHzz NFHIe|I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
LAN-5 MYPxTHRUKGG|c3H5 MYXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVEGQLUWgZ4VtdHN? Ml\4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Caco-2 NUTodGIyS3m2b4TvfIlkcXS7IHHzd4F6 NWW4bJFUPDhiaH;1dpM> M3TkN2RmfGW{bXnuZZRqd25ib3[gTWM2OCC4YXz1[ZMh\m:{IHnubIljcXSrb36gc4YhW0GUUz3Dc3YuOiCrbnT1Z4VlKGO7dH;0c5hq[2m2eTDv[kBE[WOxLUKgZ4VtdHNiYX\0[ZIhPDhiaH;1dpMh[nliaHnnbEBkd262ZX70JIlu[WerbnesJGlEPTBiPTC1MlY5KM7:TT6= MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyPVg4OzRxJ{7DbGVOSkx:L3G+
Caco-2 MXPUc5hq[2m2eTDhd5NigQ>? MmTwOFghcG:3coO= MXTUc5hq[2m2eTDh[4FqdnO2IFPhZ48uOiClZXzsd{Bl\XSncn3pcoVlKGG2IES4JIhwfXK|IHL5JIlvfHKjY3XscJVt[XJiQWTQJINwdmOnboTyZZRqd25idYPpcochfGinIFPlcIxVcXSncj3HcI8hVHWvaX7ld4NmdnRiQ3XscEBXcWGkaXzpeJkhSXO|YYmsJGNEPTBiPTCxNE44OSEQvF2u MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyPVg4OzRxJ{7DbGVOSkx:L3G+

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-ERK / p-SAPK / p-JNK; 

PubMed: 29285232     


Western blot analysis of protein levels of phosphoERK1/2, phospho-SAPK/JNK, total ERK1/2 and total SAPK/JNK in HCC cells treated with lonafarnib as indicated.

PARP / cleaved-PARP / pro-caspase3 / cleaved-caspase3 / Bcl-2; 

PubMed: 29285232     


Western blot analysis of levels of apoptosis-related protein including PARP, cleaved PARP, pro-Caspase-3, cleaved Caspase-3 and Bcl-2 in HCC cells treated with lonafarnib as indicated. The asterisk indicates a non-specific band.

Cyclin D / CDK6 / CDK4 / SKP2; 

PubMed: 29285232     


Western blot analysis of levels of cell cycle-related proteins including Cyclin D, CDK4, CDK6 and SKP2 in HCC cells treated with lonafarnib as indicated.

LC3A / LC3B ; 

PubMed: 29069775     


Lonafarnib, inhibitor for farnesyl transferase, significantly induced the expression of autophagy marker.

29285232 29069775
Growth inhibition assay
Cell number; 

PubMed: 29069775     


Lonafarnib, inhibitor for farnesyl transferase, significantly inhibited the cell proliferation. 

Cell viability; 

PubMed: 15860663     


PLC1 cells were treated with the indicated concentrations of SCH66336 for the indicated amount of time. Viability is expressed as the percentage of trypan blue-excluding cells of the total number of cells present. 

29069775 15860663
体内研究 SCH66336 抑制HTBI77人肺癌裸鼠移植模型中的瘤生长,抑制作用呈剂量依赖性[1]。在NOD/SCID免疫缺陷小鼠皮下注射XEN01, XEN05或XEN08 GBM建立肿瘤移植模型,SCH66336 以 50 mg/kg剂量口服灌胃21天后,可抑制肿瘤生长,抑制率高达69%[3]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:[2]
- 合并
  • Cell lines: UMSCC10B, UMSCC14B, UMSCC17B, UMSCC22B, 和UMSCC35, UMSCC38 细胞
  • Concentrations: 0.1 μM - 8 μM
  • Incubation Time: 24 小时
  • Method: 细胞铺板于96孔板中,后续培养5天,据此确定起始密度。24小时后,用不同浓度SCH66336处理细胞。SCH66336溶解于DMSO。对照组细胞用同样量的DMSO处理。5天后用SRB法检测细胞数量。生长抑制的百分比的计算公式为:增长抑制百分比=(1−/At/Ac)×100,At和Ac分别代表实验组和对照组的吸收值。IC 50值由剂量反应曲线确定。
    (Only for Reference)
动物实验:[3]
- 合并
  • Animal Models: 6–12周龄NOD/SCID 小鼠
  • Dosages: 50 mg/kg
  • Administration: 口服
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 127 mg/mL (198.8 mM)
Water Insoluble
Ethanol '127 mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 638.82
化学式

C27H31Br2ClN4O2

CAS号 193275-84-2
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02579044 Enrolling by invitation Drug: Everolimus and lonafarnib Progeria Boston Children''s Hospital December 2015 Phase 1|Phase 2
NCT02527707 Completed Drug: lonafarnib|Drug: Ritonavir Chronic Delta Hepatitis Eiger BioPharmaceuticals|Hannover Medical School September 2015 Phase 2
NCT02430194 Completed Drug: lonafarnib|Drug: Ritonavir|Drug: PEG IFN-a Chronic Hepatitis D Infection Eiger BioPharmaceuticals|Ankara University December 2014 Phase 2
NCT02430181 Completed Drug: lonafarnib|Drug: PEG IFN-a|Drug: Ritonavir Chronic Hepatitis D Infection Eiger BioPharmaceuticals November 2014 Phase 2
NCT01495585 Completed Drug: Lonafarnib|Other: Placebo Hepatitis D National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC) December 2011 Phase 2
NCT01232881 Terminated Procedure: Tumor Sample|Procedure: Serum Sample Breast Cancer Hoosier Cancer Research Network|United States Department of Defense|Indiana University School of Medicine|Emory University August 2009 --

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

Transferase Signaling Pathway Map

Tags: 购买Lonafarnib (SCH66336) | Lonafarnib (SCH66336)供应商 | 采购Lonafarnib (SCH66336) | Lonafarnib (SCH66336)价格 | Lonafarnib (SCH66336)生产 | 订购Lonafarnib (SCH66336) | Lonafarnib (SCH66336)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID